Join
Live feed
·
PRReleasevia Quantisnow
Tiziana Life Sciences Ltd. logo

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

ByQuantisnow·Wall Street's wire, on your screen.
TLSA· Tiziana Life Sciences Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TLSA (Tiziana Life Sciences Ltd.) and more on Quantisnow.